# PK and Safety of SI-722 in IC/BPS

> **NCT04208087** · PHASE1,PHASE2 · COMPLETED · sponsor: **Seikagaku Corporation** · enrollment: 33 (actual)

## Conditions studied

- Interstitial Cystitis
- Bladder Pain Syndrome

## Interventions

- **DRUG:** SI-722
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04208087
- **Lead sponsor:** Seikagaku Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-30
- **Primary completion:** 2021-01-12
- **Final completion:** 2021-01-12
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2023-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04208087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04208087, "PK and Safety of SI-722 in IC/BPS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04208087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*